<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Biochemical Engineering</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A5739A5-B58F-47C1-B425-94267E91DEE1"><gtr:id>5A5739A5-B58F-47C1-B425-94267E91DEE1</gtr:id><gtr:name>Technology Strategy Board</gtr:name><gtr:address><gtr:line1>Block B, Floor 1</gtr:line1><gtr:line2>North Star House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1JF</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/98BB23FC-2B93-48A0-B929-23AA0BDDC60B"><gtr:id>98BB23FC-2B93-48A0-B929-23AA0BDDC60B</gtr:id><gtr:firstName>Mike</gtr:firstName><gtr:surname>Hoare</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=TS%2FH001093%2F1"><gtr:id>BAF88473-413F-4980-953E-EE96A66E4419</gtr:id><gtr:title>Manufacture of low cost, high efficacy vaccines</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>TS/H001093/1</gtr:grantReference><gtr:abstractText>There is a major need for preventative healthcare to reduce the growing load on the budgets required for medical treatment of conditions such as hepatitis, cervical cancer and seasonal and pandemic flu. Vaccines provide such a means to address this increasing challenge to society. However there is a need for new candidates which offer the potential for improved protection at lower cost and to greater numbers of the community. Such new candidates must not only exhibit medical effectives and safety but also must be suitable for manufacture at the industrial scale. The new candidates described in this proposal offer the potential to construct new molecules, so-called fusions, which can both use the benefit of the body's immune system to deliver directly to the sites in the body the agent to elicit the protective (immune) response. The technology to be developed in this programme will also provide the early test bed of the manufacturability of these new candidates when only small amounts of precious material are available. In this way a range of candidates may be testesd and, if neccesary new types of fusions to be designed which not only offer high levels of protection but are more readily manufactured, stored, and supplied to the patient. The research sequence will be to agree specifications of validatable large-scale bioprocesses for fusion protein production and purification. These processes will be characterised to quantify the regions of high stress which may result in damage to the fusion proteins. Ultra scale-down devices will be used to mimic these high stress regions and used to test small qualities of fusion proteins and their response to stress. These results will be used to predict the large-scale operation and these predicitions verified in collaboration with a programme partner, Cobra. This verified platform will be used to examine new fusion protein constructs and help in selection and choice of candidates for large-scale development.</gtr:abstractText><gtr:fund><gtr:end>2011-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>78411</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>17500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Industry Doctoral Training Centre (IDTC)</gtr:department><gtr:description>EPSRC IDTC</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/G034656/1</gtr:fundingRef><gtr:id>9A227929-5B11-4D37-9CD5-27B2ADE5D919</gtr:id><gtr:outcomeId>r-6911425615.57835506832c8c</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>?Details of emerging economic and societal impact arising from the award that you are reporting on (including how it has evolved)
Research programmes are now in place to help speed availability of new vaccines
?A summary of how the findings from your award are impacting the public, private or third/voluntary sectors, and elsewhere
The findings are part of evidence that such a new route to manufacturing discovery is feasible 
?Challenges overcome to achieve impact
Winning of new research funding from ne sources</gtr:description><gtr:id>B8A57EAD-068D-4D98-B0AD-79A2FD61B54E</gtr:id><gtr:impactTypes/><gtr:outcomeId>56dea36ccf3018.15832810</gtr:outcomeId><gtr:sector>Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>- What were the most significant achievements from the award?
A route for the rapid discovery for effective manufacture of net generation vaccines

- To what extent were the award objectives met? If you can, briefly explain why any key objectives were not met. 
Fully met in terns of engineering discovery tools</gtr:description><gtr:exploitationPathways>- How might the findings be taken forward and by whom?
Researchers in area of development of new vaccine candidates</gtr:exploitationPathways><gtr:id>63856402-E222-4275-B01C-49936519D4D5</gtr:id><gtr:outcomeId>56dea33b9576d0.78812415</gtr:outcomeId><gtr:sectors><gtr:sector>Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>13367F2D-9B7C-4773-9FA9-7ABBF5DBFDDB</gtr:id><gtr:title>An ultra scale-down characterization of low shear stress primary recovery stages to enhance selectivity of fusion protein recovery from its molecular variants.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f04e9f385893157e80098be9abd7b98"><gtr:id>9f04e9f385893157e80098be9abd7b98</gtr:id><gtr:otherNames>Lau EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>5461edcaf1c0a3.93647856</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">TS/H001093/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>E48C802F-8897-4353-910A-09D09331BB82</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Medical science &amp; disease</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>